| Q31018336 | A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma |
| Q51054715 | A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. |
| Q38611422 | A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma |
| Q34762754 | CLCA2 as a novel immunohistochemical marker for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung |
| Q38947180 | Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease |
| Q57990927 | Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning |
| Q38097027 | Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification |
| Q37651236 | Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India |
| Q47396647 | Combining deep learning and coherent anti-Stokes Raman scattering imaging for automated differential diagnosis of lung cancer |
| Q54477690 | Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. |
| Q39723585 | DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer |
| Q36354323 | Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases |
| Q93354282 | Distinct lung cancer subtypes associate to distinct drivers of tumor progression |
| Q36673780 | Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma |
| Q35919451 | Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis |
| Q42153363 | Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens |
| Q84882860 | Endobronchial ultrasound fine-needle aspiration biopsy of pulmonary non-small cell carcinoma with subclassification by immunohistochemistry panel |
| Q43089872 | Endobronchial ultrasound-guided transbronchial needle aspiration: a maturing technique |
| Q34281884 | Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. |
| Q56915178 | Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma |
| Q33611881 | Gene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC. |
| Q44280426 | Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis |
| Q38164052 | Histo-cytological diagnostic accuracy in lung cancer |
| Q36498167 | IMP3 can predict aggressive behaviour of lung adenocarcinoma |
| Q97528967 | Identification of Prognostic Biomarkers for Multiple Solid Tumors Using a Human Villi Development Model |
| Q43196068 | Immunoexpression of napsin A in renal neoplasms |
| Q51563657 | Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. |
| Q37056876 | Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada |
| Q44646862 | Infrared spectral histopathology (SHP): a novel diagnostic tool for the accurate classification of lung cancer |
| Q51334457 | Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. |
| Q36962487 | Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers |
| Q58102094 | Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype? |
| Q34109148 | Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer |
| Q45910147 | Mesothelioma with signet-ring cell features: report of 23 cases. |
| Q102071743 | Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity |
| Q27690919 | Molecular pathology of non-small cell lung cancer: a practical guide |
| Q61800801 | Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer |
| Q35702852 | N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice |
| Q50474123 | Napsin A is a specific marker for ovarian clear cell adenocarcinoma. |
| Q37595541 | Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease |
| Q53407464 | Primary combined neuroendocrine carcinoma (small-cell type) and squamous cell carcinoma of the colon. |
| Q47371241 | Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma. |
| Q38437389 | Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches |
| Q36090076 | Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens |
| Q26774726 | Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era |
| Q38203468 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer |
| Q34747336 | Semi-nested real-time reverse transcription polymerase chain reaction methods for the successful quantitation of cytokeratin mRNA expression levels for the subtyping of non-small-cell lung carcinoma using paraffin-embedded and microdissected lung bi |
| Q37237353 | Skeletal muscle metastases on magnetic resonance imaging: analysis of 31 cases |
| Q34426010 | Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer |
| Q38112386 | Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice |
| Q83889262 | The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma |
| Q45774429 | The diagnostic utility of the minimal carcinoma triple stain in breast carcinomas |
| Q40477156 | The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas. |
| Q39500444 | The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer |
| Q38822314 | The impact of immunohistochemistry on the classification of lung tumors. |
| Q91757966 | The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung |
| Q39233250 | Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma |
| Q37594182 | Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma |
| Q34067972 | p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma |
| Q35227440 | p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. |
| Q42435605 | ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization |